123 related articles for article (PubMed ID: 12086854)
21. Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein.
Kondo K; Klco J; Nakamura E; Lechpammer M; Kaelin WG
Cancer Cell; 2002 Apr; 1(3):237-46. PubMed ID: 12086860
[TBL] [Abstract][Full Text] [Related]
22. Von Hippel-Lindau tumor suppressor protein and hypoxia-inducible factor in kidney cancer.
Maynard MA; Ohh M
Am J Nephrol; 2004; 24(1):1-13. PubMed ID: 14654728
[TBL] [Abstract][Full Text] [Related]
23. Specific oncolytic effect of a new hypoxia-inducible factor-dependent replicative adenovirus on von Hippel-Lindau-defective renal cell carcinomas.
Cuevas Y; Hernández-Alcoceba R; Aragones J; Naranjo-Suárez S; Castellanos MC; Esteban MA; Martín-Puig S; Landazuri MO; del Peso L
Cancer Res; 2003 Oct; 63(20):6877-84. PubMed ID: 14583486
[TBL] [Abstract][Full Text] [Related]
24. Up-regulation of hypoxia-inducible factor 2alpha in renal cell carcinoma associated with loss of Tsc-2 tumor suppressor gene.
Liu MY; Poellinger L; Walker CL
Cancer Res; 2003 May; 63(10):2675-80. PubMed ID: 12750296
[TBL] [Abstract][Full Text] [Related]
25. Regulation of tyrosine hydroxylase promoter activity by the von Hippel-Lindau tumor suppressor protein and hypoxia-inducible transcription factors.
Schnell PO; Ignacak ML; Bauer AL; Striet JB; Paulding WR; Czyzyk-Krzeska MF
J Neurochem; 2003 Apr; 85(2):483-91. PubMed ID: 12675925
[TBL] [Abstract][Full Text] [Related]
26. Silencing of epidermal growth factor receptor suppresses hypoxia-inducible factor-2-driven VHL-/- renal cancer.
Smith K; Gunaratnam L; Morley M; Franovic A; Mekhail K; Lee S
Cancer Res; 2005 Jun; 65(12):5221-30. PubMed ID: 15958567
[TBL] [Abstract][Full Text] [Related]
27. Regulation of the HIF pathway: enzymatic hydroxylation of a conserved prolyl residue in hypoxia-inducible factor alpha subunits governs capture by the pVHL E3 ubiquitin ligase complex.
Mole DR; Pugh CW; Ratcliffe PJ; Maxwell PH
Adv Enzyme Regul; 2002; 42():333-47. PubMed ID: 12123724
[No Abstract] [Full Text] [Related]
28. Regulation of HIF prolyl hydroxylases by hypoxia-inducible factors.
Aprelikova O; Chandramouli GV; Wood M; Vasselli JR; Riss J; Maranchie JK; Linehan WM; Barrett JC
J Cell Biochem; 2004 Jun; 92(3):491-501. PubMed ID: 15156561
[TBL] [Abstract][Full Text] [Related]
29. Vascular endothelial growth factor-B and vascular endothelial growth factor-C expression in renal cell carcinomas: regulation by the von Hippel-Lindau gene and hypoxia.
Gunningham SP; Currie MJ; Han C; Turner K; Scott PA; Robinson BA; Harris AL; Fox SB
Cancer Res; 2001 Apr; 61(7):3206-11. PubMed ID: 11306510
[TBL] [Abstract][Full Text] [Related]
30. Oxygen sensors and angiogenesis.
Maxwell PH; Ratcliffe PJ
Semin Cell Dev Biol; 2002 Feb; 13(1):29-37. PubMed ID: 11969369
[TBL] [Abstract][Full Text] [Related]
31. The von Hippel-Lindau tumor suppressor complex and regulation of hypoxia-inducible transcription.
Conaway RC; Conaway JW
Adv Cancer Res; 2002; 85():1-12. PubMed ID: 12374282
[No Abstract] [Full Text] [Related]
32. p300 relieves p53-evoked transcriptional repression of hypoxia-inducible factor-1 (HIF-1).
Schmid T; Zhou J; Köhl R; Brüne B
Biochem J; 2004 May; 380(Pt 1):289-95. PubMed ID: 14992692
[TBL] [Abstract][Full Text] [Related]
33. Hypoxia-inducible factor-1-dependent repression of E-cadherin in von Hippel-Lindau tumor suppressor-null renal cell carcinoma mediated by TCF3, ZFHX1A, and ZFHX1B.
Krishnamachary B; Zagzag D; Nagasawa H; Rainey K; Okuyama H; Baek JH; Semenza GL
Cancer Res; 2006 Mar; 66(5):2725-31. PubMed ID: 16510593
[TBL] [Abstract][Full Text] [Related]
34. Tuberous sclerosis complex protein 1 expression is affected by VHL Gene alterations and HIF-1α production in sporadic clear-cell renal cell carcinoma.
Damjanovic SS; Ilic BB; Beleslin Cokic BB; Antic JA; Bankovic JZ; Milicevic IT; Rodic GS; Ilic DS; Todorovic VN; Puskas N; Tulic CD
Exp Mol Pathol; 2016 Dec; 101(3):323-331. PubMed ID: 27845047
[TBL] [Abstract][Full Text] [Related]
35. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
Zatyka M; da Silva NF; Clifford SC; Morris MR; Wiesener MS; Eckardt KU; Houlston RS; Richards FM; Latif F; Maher ER
Cancer Res; 2002 Jul; 62(13):3803-11. PubMed ID: 12097293
[TBL] [Abstract][Full Text] [Related]
36. Identification of novel VHL target genes and relationship to hypoxic response pathways.
Maina EN; Morris MR; Zatyka M; Raval RR; Banks RE; Richards FM; Johnson CM; Maher ER
Oncogene; 2005 Jun; 24(28):4549-58. PubMed ID: 15824735
[TBL] [Abstract][Full Text] [Related]
37. Expression of HIF-1 and ubiquitin in conventional renal cell carcinoma: relationship to mutations of the von Hippel-Lindau tumor suppressor gene.
Hughson MD; He Z; Liu S; Coleman J; Shingleton WB
Cancer Genet Cytogenet; 2003 Jun; 143(2):145-53. PubMed ID: 12781449
[TBL] [Abstract][Full Text] [Related]
38. In vitro and in vivo models analyzing von Hippel-Lindau disease-specific mutations.
Rathmell WK; Hickey MM; Bezman NA; Chmielecki CA; Carraway NC; Simon MC
Cancer Res; 2004 Dec; 64(23):8595-603. PubMed ID: 15574766
[TBL] [Abstract][Full Text] [Related]
39. Renal cancer cells lacking hypoxia inducible factor (HIF)-1alpha expression maintain vascular endothelial growth factor expression through HIF-2alpha.
Shinojima T; Oya M; Takayanagi A; Mizuno R; Shimizu N; Murai M
Carcinogenesis; 2007 Mar; 28(3):529-36. PubMed ID: 16920734
[TBL] [Abstract][Full Text] [Related]
40. Differences in Tumor VHL Mutation and Hypoxia-inducible Factor 2α Expression Between African American and White Patients with Clear Cell Renal Cell Carcinoma.
Callahan CL; Moore L; Lenz P; Linehan WM; Nickerson ML; Rothman N; Purdue MP
Eur Urol; 2019 May; 75(5):882-884. PubMed ID: 30655088
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
